Nexalin's device administers a frequency-based waveform that is designed to treat patients in a pain-free and undetectable manner. The Gen-2 and Gen-3 stimulation techniques rely on strategically ...
On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease.
Nanotechnology represents one of the most transformative fields in modern science, bridging physics, chemistry, biology, and engineering to create breakthroughs that redefine how the world works. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback